Royalty Report: Drugs, Cancer, Therapeutic – Collection: 27119

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Biotechnology
  • Pharmaceuticals
  • Disease
  • Delivery
  • Diagnostic
  • cell therapy

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27119

License Grant
The Company entered into an exclusive worldwide licensing agreement with the Licensor, government public health organization, for mesothelin mab.
License Property
Mesothelin Mab targets mesothelin receptors on cancer cells and delivers a cytotoxin to destroy the cancer cell while leaving normal cells alone.  Mesothelin Mab is expected to enter Phase I clinical studies in the later part of 1999. Mesothelin Mab specifically targets those tumors that express the mesothelin antigen on the surface of cancer cells.  Phase I to be initiated in 4th Quarter 1999.
Field of Use
Cancer Indication Ovarian, Head, Neck, Mesotheliomas.

IPSCIO Record ID: 4947

License Grant
The Licensor, government organization, grants the Licensee an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.
License Property
Serial Number(s) of Patent Application(s) that are 'Licensed Patent Rights' – licensed on an exclusive basis USPA 08/776,271, entitled, 'Mesothelium Antigen and Methods and Kits for Targeting It', inventors Dr. Ira H. Pastan (NCI) and Dr. Kai Chang (NCI) = E-002-96/1 ; and USPA 60/067,175, entitled 'Antibodies, Including Fv Molecules, and Immunoconjugates having High Binding Affinity for Mesothelin and Methods for Their Use', inventors Dr. Ira H. Pastan (NCI) and Dr. Partha Chowdhury (NCI) =E-021-98/0 Serial Number(s) of Patent(s) and Patent Application(s) that are 'Background Patent Rights' and licensed on a non-exclusive basis USPN 4,892,827 (=USSN 06/911,227), entitled, 'Recombinant PSEUDOMONAS Exotoxin Construction of an Active Immunotoxin with Low Side Effects', inventors Drs. Ira H. Pastan (NCI), Sankar Adhya (NCI), and David FitzGerald (NCI), – excluding any foreign equivalents corresponding to 4,892,827 (= USSN 06/911,227 ) =E-385-96/0 . USPN 5,747,654 (= USPA 08/077,252) enabled, 'Recombinant Disulfide- Stabilized Polypeptide Fragments Having Binding Specificity', inventors Drs. Ira H. Pastan (NCI), Byungkook Lee (NCI), Sun-Hee Jung (NCI), Ulrich Brinkmann (NC1) =E-163-93/0 . USPA 09/002,753 (=Division of USPA 08/077,252), entitled 'Recombinant Disulfide-Stabilized Polypeptide Fragrnents Having Binding Specificity', inventors Drs. Ira H. Pastan (NCl), Byungkook Lee (NCI), Sun-Hee Jung (NC1), Ulrich Brinkman (NCI) =E-163-93/4 . ; The Licensed Fields of Use is limited to the use of the SS(dsFv)-P-38 immunotoxin, and the relevant patent applications defined under Licensed Patent Rights and/or Background Patent Rights, for the IN VIVO therapeutic treatment of ovarian carcinomas and mesotheliomas – clinical trial.
Field of Use
The Licensed Fields of Use is limited to the use of the SS(dsFv)-P-38 immunotoxin, and the relevant patent applications defined under Licensed Patent Rights and/or Background Patent Rights, for the IN VIVO therapeutic treatment of ovarian carcinomas and mesotheliomas.

IPSCIO Record ID: 203490

License Grant
This agreement is to develop and commercialize certain of the antibodies produced and evaluated by the Parties pursuant to such collaborative relationship and/or other antibodies generated against the target proteins identified within the collaboration and selected by Licensee for development, and the Parties desire for Licensor to have all rights to those targets and antibodies coming out of the collaborative research that Licensee does not elect to further develop.

For the Screening license, Licensor grants a non-exclusive license under the Licensors Technology and Licensors interest in any Joint Know-How in the United States solely as necessary to carry out the Research hereunder during the Research Term.  Such license shall not be sublicensable.

For the Development and Commercialization license, Licensor grants an exclusive license, with the right to sublicense, under the Licensed Know-How and the Licensed Patents to generate and screen Licensees Mabs; and create Derivatives of Selected Mabs and Licensee Mabs, and develop, make, have made, use, sell, offer for sale, have sold, import and have imported Licensed Products for use in the Commercial Field in the Territory.

And, Licensor grants an exclusive license, with the right to sublicense, under the Licensed Know-How and the Licensed Patents to use the Selected Targets to generate and screen Licensee Mabs, and develop Licensed Mabs in the Commercial Field in the Territory during the Term.

License Property
Licensor has proprietary immunization and other methods for generating Mabs against cell surface proteins, and possesses certain proprietary cell lines or will acquire cell lines which have cell surface proteins with relevance to ovarian cancer.

Licensor Technology shall mean any Know-How that is and all Patents claiming inventions that are useful or necessary to generate and to screen Mabs binding to a Molecular Target, including without limitation methods of immunization, methods for maintaining and handling cell lines expressing Mabs, production and freezing media, and antibody screening facilitation tools including without limitation CellArrayâ„¢,  controlled by Licensor as of the effective date and during the term, and disclosed by Licensor to Licensee during the Term.

Joint Know-How shall mean any Know-How jointly invented by both Parties in the conduct of the Research, invented by Licensor in the conduct of the Research as a direct result of its use of Licensees Technology, or, invented by Licensee in the conduct of the Research as a direct result of its use of Licensors Technology.

Licensed Product shall mean any pharmaceutical product containing a Licensed Mab.

Cytotoxic Compound shall mean any Cytotoxic compound and all variants, fragments or derivatives thereof, whether produced by a botanical source, natural fermentation or chemical synthesis,  which is, in any case, controlled by Licensee.

Naked Mab Licensed Product shall mean any Licensed Product that is not a Cytotoxin-Coupled Licensed Product.

Antigen shall mean any protein, peptide or carbohydrate or other composition, and/or any fragment, peptide and/or epitope thereof which causes an immune response that produces antibodies.

Field of Use
The Major Indication shall mean an one of prostate cancer, breast cancer, lung cancer, colorectal cancer, non-Hodgkins lymphoma, bladder cancer, melanoma, uterine cancer, leukemia, kidney cancer, head and neck cancer, pancreatic cancer or ovarian cancer.

The Commercial Field shall mean therapeutic products employing Mabs, alone or in conjunction with other ingredients, to treat cancer in humans.

IPSCIO Record ID: 26237

License Grant
The agreement granted exclusive development and commercialization rights to the Licensor's fully human, immune-oncology anti-PD-L1 monoclonal antibody (mAb) STI-A1014 for the greater Chinese market.
License Property
The mAb is novel, proprietary, and fully human. The Licensor is currently developing production quality cell lines for their anti-PD-L1 antibody, STI-A1010, which will lay the foundation for Investigational New Drug, or IND, -enabling studies in the U.S. in 2014. The Licensor anticipates that a Phase I clinical trial for their lead candidate anti-PD-L1 antibody could be initiated in 2015.  The mAb's are derived from the Licensor's proprietary G-MAB® library platform and chosen based on cancer targets.

Patent Antigen binding proteins that bind PD-L1

Field of Use
The individual mAbs discovered from the Licensor's library potentially give a multitude of therapeutic options to target and attack cancer cells. This could be either directly, such as (i) recruitment of immune effector functions, including, but not limited to, antibody-dependent cellular cytotoxicity, or ADCC, or (ii) antagonistic suppression of cellular signaling processes required for cancer proliferation and metastasis; or indirectly, via modulation host biology, such as (a) enhancement of immune activity in the tumor, or (b) normalization of the tumor microenvironment, including anti-angiogenesis for cutting off blood supplies to the tumor.

IPSCIO Record ID: 256217

License Grant
In the original agreement Licensor, government public health organization, grants an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.

The Licensor grants a co-exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use. For purposes of this Agreement co-exclusive shall mean that at any time only the Licensee and its Affiliates, on the one hand, and one other Licensee and its Affiliates, on the other hand, shall at any time have a license or other right from the Licensor under the Licensed Patent Rights in the Licensed Territory in the Licensed Fields of Use.

License Property
The agreement is for a specified constructs, formulations and doses of specified Licensed Products in a specified cancer indication, the statistical demonstration in a pivotal Phase 3 Clinical Study of safety and efficacy, sufficient to support a BLA submission by the Licensee for such specified construct, formulation and dose of such specified Licensed Product for the treatment of such specified cancer indication.
Field of Use
Licensed Fields of Use, defined in the original agreeement is
–  Development and manufacture of synovial sarcoma breakpoint X-2 (SSX-2) T cell receptor (TCR)-based autologous peripheral blood T cell therapy products as set forth in the Licensed Patent Rights for the treatment of head and neck cancer, hepatocellular carcinoma, melanoma, prostate cancer, and sarcoma.
–  Development and manufacture of epidermal growth factor receptor variant III (EGFRvIII) chimeric antigen receptor (CAR)-based autologous peripheral blood T cell therapy products as set forth in the Licensed Patent Rights for the treatment of brain cancer, head and neck cancer, and melanoma.
–  Development and manufacture of synovial sarcoma breakpoint X-2 (SSX-2) T cell receptor (TCR)-based autologous peripheral blood T cell therapy products as set forth in the Licensed Patent Rights for the treatment of breast cancer, ovarian cancer, and colorectal cancer.
–  Development and manufacture of epidermal growth factor receptor variant III (EGFRvIII) chimeric antigen receptor (CAR)-based autologous peripheral blood T cell therapy products as set forth in the Licensed Patent Rights for the treatment of breast cancer, ovarian cancer, and colorectal cancer.
For purposes of the Agreement, autologous peripheral blood T cell therapy products shall mean T cell or precursor products and compositions derived from blood, bone marrow, lymph nodes and thymus and, for the avoidance of doubt, shall exclude tumor-infiltrating lymphocytes (TILs).

IPSCIO Record ID: 368653

License Grant
For the options and commercial licenses, the Licensor of Switzerland, an international community of scientists focused on cancer research, grants a Non-exclusive, worldwide license, with rights to grant sub-licenses, under Licensor Patent Rights and Know-How to research, develop, make, have made, use, import, offer for sale, sell and have sold Licensed Products in the Field.
License Property
Licensor owns or has the rights to patents including those relating to Full length Antigens and Part Length Antigens.

Full Length Antigens shall mean the full length protein forms of the Licensor Antigens NY-ES0-1, NY-BR-1 and NY-C0-58.

Part Length Antigens shall mean Polypeptide Sequence forms of the Licensor Antigens MAGE-A3, Melan-A, and SSX2.

Field of Use
Agreement covers potential antigens being studied in non-small-cell-lung, ovarian, and bladder cancers, as well as melanoma.

These antigens, previously identified and characterized immunologically by Licensor , will add to new Licensee development programs for a range of cancer types. NY-ESO-1, MAGE3, and MelanA, in particular, are being studied in non-small-cell-lung, ovarian, and bladder cancers, as well as melanoma in an extended series of Phase I/II programs conducted by the Licensor and its collaborators.

This agreements focus is cancer immunotherapy.

IPSCIO Record ID: 27133

License Grant
The Licensor, government public health organization, hereby grants and Licensee accepts, subject to the terms and conditions of this Agreement, an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, and to sell and have sold any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.  Upon written approval by PHS which will be given within thirty (30) days of a written request by Licensee, said approval not to be unreasonably withheld, Licensee may enter into sublicensing agreements under the Licensed Patent Rights.
License Property
Patent(s) or Patent Application(s) that are Licensed Patent Rights
– U.S. Patent 5,614,191 issued March 25, 1997
– USSN 08/821,840 (div of 08/404,685) filed March 21, 1997
Patent(s) or Patent Application(s) that are Background Patent Rights
– U.S. Patent 4,892,827 issued January 9, 1990

The Company entered into an exclusive worldwide licensing agreement with the National Institutes of Health and the FDA to develop and commercialize an IL-13 chimeric protein therapy.

The IL-13 chimeric protein is the fusion of the receptor-binding ligand IL-13 with a derivative of Pseudomonas exotoxin (PE38QQR).  Research has demonstrated that some solid tumors express high numbers of IL-13 receptors on their cell surfaces.  These receptor sites become a specific target for the IL-13 chimeric protein for inducing cytotoxicity at nanogram concentrations.  IL-13 Chimeric Protein Exotoxin is a genetically engineered compound incorporating a highly toxic material that destroys cells once linked to the target receptor on its surface.  Pre-clinical trials ongoing, initiate Phase I in the 2nd Quarter, 1999.

Cancer Indication Renal Cell, Brain, Kaposi's Sarcoma, Breast.

Field of Use
Licensed Fields of Use To use of the chimeric molecule hIL-13-PE38QQR or cphIL-13-PE38QQR to treat cancer.

IPSCIO Record ID: 29400

License Grant
A Company focused on immunotherapy treatments for certain cancers, chronic hepatitis B and C and embolotherapy treatments for tumors, today announced that its wholly owned Irish subsidiary, the Licensor, has entered into a Manufacturing and Supply Agreement with the Licensee, a subsidiary of a Italian company, for the manufacturing, licensing and distribution of OvaRex® MAb to its remaining unlicensed European territories, which include the U.K., Ireland, France, Sweden, Finland and other countries.
License Property
Pursuant to the Agreements, existing European licensing partners will market and distribute the product throughout most of Europe and the Middle East. The Manufacturing and Supply Agreement is expected to be ratified by the Licensee's Board of Directors when they next meet in January 2007. After such ratification, the Licensee will manufacture and supply OvaRex® MAb for all of the Licensor's European licensing partners.

OvaRex® MAb is intended for the treatment of ovarian cancer.

Field of Use
The Field of Use apply to the healthcare industry relating to treatments for tumors of certain cancers.

IPSCIO Record ID: 229530

License Grant
The Licensor of United Kingdom and Licensee into an exclusive license agreement granting an exclusive license, with the right to sublicense, under certain patents and technology relating to the de-immunization of Licensees cytotoxin Bouganin.  Licensee has the worldwide exclusive right, with the right to sublicense, under the licensed patents and technology to, among other things, make, have made, use or sell products incorporating deBouganin.
License Property
The de-immunized cytotoxin is known as deBouganin, and has been incorporated into Licensees product candidate, VB6-845d, relating to the treatment of cancer.
Field of Use
This agreement is for therapeutic and in vivo diagnostic purposes in humans.  Licensee is a biologics oncology company focused primarily on designing, engineering and developing targeted protein therapeutics, or TPTs, a single protein therapeutics composed of targeting moieties genetically fused via a peptide linker domain to cytotoxic protein payloads that are produced through proprietary recombinant one-step manufacturing process, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells.

IPSCIO Record ID: 275366

License Grant
Licensor of Denmark grants Licensor of Switzerland. the remaining rights to ofatumumab.

The product, Ofatumumab, is being commercialized by Licensee.

License Property
The Product, ofatumumab, is marketed as Arzerra for certain indications of chronic lymphocytic leukemia (CLL).

Ofatumumab is a human IgG1k mAb that targets an epitope on the CD20 molecule, which is found on the surface of B-cells, the type of cell which is believed to trigger the inflammatory process that leads to multiple sclerosis (MS).

Field of Use
Ofatumumab for the treatment of cancer and also for non-cancer treatments.  Ofatumumab, previously approved for certain CLL indications, is in pivotal Phase III testing by Licensee for the treatment of RMS, with the Phase III ASCLEPIOS I and II studies.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.